Devin Heinlein
Nurse Practitioner · Sebewaing, MINPI 1184156028
Payments from drug & device makers
Across 81 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$416
- Otsuka America Pharmaceutical, Inc.$154
- Pfizer$130
- Lilly USA, LLC$123
- GSK$109
- AbbVie$102
- plus $427 from 15 others
What the payments were for
- Food & beverage$1,461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $416 |
| Otsuka America Pharmaceutical, Inc. | 7 | $154 |
| Pfizer | 7 | $130 |
| Lilly USA, LLC | 8 | $123 |
| GSK | 7 | $109 |
| AbbVie | 5 | $102 |
| Biohaven Pharmaceuticals, Inc. | 2 | $96 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Exact Sciences | 2 | $36 |
| Inspire Medical Systems, Inc. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Bioventus LLC | 1 | $24 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Alkermes, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Insulet Corporation | 1 | $17 |
| Medtronic | 1 | $15 |
| Abbott | 1 | $13 |
How this compares
$1,461 in reported general payments places this provider in the 85th percentile of 3,351 nurse practitioner providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 35 | $78,175 |
| EliquisApixaban | 56 | $65,259 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $56,027 |
| RybelsusSemaglutide | 24 | $47,127 |
| JardianceEmpagliflozin | 27 | $44,809 |
| XareltoRivaroxaban | 31 | $43,742 |
| TrulicityDulaglutide | 16 | $14,931 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $11,058 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $7,928 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 145 | $2,439 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $1,958 |
| Potassium Chloride | 69 | $1,938 |
| Pravastatin Sodium | 108 | $1,842 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 11 | $1,722 |
| Levothyroxine Sodium | 164 | $1,712 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $416 | $125,30359 claims |
| PfizerEliquis | $130 | $65,25956 claims |
| GSKTrelegy Ellipta | $109 | $56,02756 claims |
| Lilly USA, LLCTrulicity | $123 | $14,93116 claims |
| AbbVieArmour Thyroid | $102 | $1,03213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Sebewaing
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.